Bortezomib inhibits osteoclast activity in patients with multiple myeloma

Clinical Lymphoma & Myeloma
Geoffrey L UyRavi Vij

Abstract

The antimyeloma agent bortezomib functions as an inhibitor of nuclear factor (NF)-kappaB. Although NF-kappaB inhibition is predicted to affect osteoclast function, preclinical and clinical studies have primarily reported an effect on osteoblasts. We examined parameters of bone turnover prospectively in patients with multiple myeloma treated with bortezomib before and after autologous transplantation. Thirty-nine patients received 2 cycles of bortezomib on days 1, 4, 8, and 11 of a 21-day cycle. After high-dose melphalan with autologous stem cell transplantation, bortezomib 1.3 mg/m2 on days 1, 8, 15, and 22 of a 5-week cycle was administered as maintenance therapy. During posttransplantation bortezomib, decreases in the urinary excretion of collagen N-telopeptide indicated that bortezomib suppresses osteoclast function. The effects on osteoclasts occurred in the absence of bisphosphonate treatment and independently of changes in monoclonal protein levels. Further studies exploring the role of bortezomib as a bone protective agent could be warranted.

References

Feb 7, 1998·Genes & Development·G FranzosoU Siebenlist
May 13, 1999·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·H W WoitgeM J Seibel
Mar 18, 2004·Cancer Research·Shmuel YaccobyJoshua Epstein
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert E ColemanRichard Cook
Sep 22, 2005·British Journal of Haematology·Maurizio ZangariGuido Tricot

❮ Previous
Next ❯

Citations

Jun 11, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Chih-Wen TsengT-C Wu
Aug 13, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Ping Wu, Gareth J Morgan
Jan 15, 2014·BoneKEy Reports·Evangelos Terpos, Dimitrios Christoulas
Jan 19, 2013·Cell Death & Disease·N SévèreP J Marie
Sep 17, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marci D JonesJane B Lian
Dec 27, 2015·Life Sciences·Jerry Vriend, Russel J Reiter
Jun 26, 2012·Seminars in Hematology·Ya-Wei QiangJoshua Epstein
Jan 10, 2012·Cancer Treatment Reviews·Maurizio ZangariGuido Tricot
Jul 10, 2010·Bone·Jessica A FowlerPeter I Croucher
Nov 26, 2008·American Journal of Hematology·Matthew T Drake, S Vincent Rajkumar
Nov 20, 2013·Cancer·Mohamad MohtyEvangelos Terpos
Aug 17, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chih-Long ChangChien-Fu Hung
Oct 31, 2017·Calcified Tissue International·Fabrizio AccardiNicola Giuliani
Aug 21, 2018·Stem Cells International·Yu-Chen GuoQuan Yuan
Sep 3, 2020·British Journal of Pharmacology·Shuting SunFrank H Ebetino
Jul 25, 2021·International Journal of Molecular Sciences·Hadla Hariri, René St-Arnaud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.